Lazar E J, Frishman W H
Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY.
Drugs. 1989;38 Suppl 2:1-8. doi: 10.2165/00003495-198900382-00003.
Many antianginal agents are available for the treatment of coronary artery disease. These agents act by influencing the determinants of myocardial oxygen supply and demand. The 3 main classes of agents are the nitrates, beta-adrenergic blocking agents and the calcium entry blockers. Agents from all 3 classes have shown efficacy in treating both symptomatic and asymptomatic myocardial ischaemia. However, some patients cannot be treated with these agents because of side effects or contraindications. An ideal antianginal drug should effectively treat both angina and silent ischaemia. Additionally, it should be free of side effects, allow for maintenance of physical performance and be metabolically neutral. New agents are being developed which strive for this goal.
有多种抗心绞痛药物可用于治疗冠状动脉疾病。这些药物通过影响心肌氧供和氧需的决定因素发挥作用。主要的三类药物是硝酸盐类、β-肾上腺素能阻滞剂和钙通道阻滞剂。所有这三类药物在治疗有症状和无症状心肌缺血方面均已显示出疗效。然而，由于副作用或禁忌证，一些患者无法使用这些药物进行治疗。理想的抗心绞痛药物应能有效治疗心绞痛和无症状性缺血。此外，它应无副作用，能维持身体机能，且对代谢无不良影响。目前正在研发致力于实现这一目标的新型药物。
